Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 3 | 12 |
| List of Tables | 8 | 4 |
| List of Figures | 12 | 3 |
| Monoclonal Antibodies Market to 2017 - Introduction | 15 | 2 |
| GBI Research Report Guidance | 16 | 1 |
| Monoclonal Antibodies Market to 2017 - Market Characterization | 17 | 20 |
| Introduction | 17 | 1 |
| Stability in the Body | 17 | 1 |
| Systemic Cancer Treatment | 17 | 1 |
| Targeted Therapy | 17 | 1 |
| Monoclonal Antibody Technology | 18 | 1 |
| Hybridoma Technology | 18 | 1 |
| FuCell Technology | 18 | 1 |
| Revenue Forecasts Global | 19 | 1 |
| Prescription Population | 19 | 1 |
| Annual Cost of Therapy | 20 | 2 |
| Revenue | 22 | 1 |
| Revenue Forecasts Countrywise | 23 | 1 |
| US | 23 | 1 |
| Europe | 24 | 1 |
| Rest of the World (ROW) | 25 | 1 |
| Treatment Usage Patterns | 26 | 1 |
| The US | 26 | 2 |
| Europe | 28 | 1 |
| ROW | 29 | 1 |
| Annual Cost of Therapy | 30 | 1 |
| The US | 30 | 1 |
| Europe | 31 | 1 |
| ROW | 32 | 1 |
| Global MAbs Trends | 33 | 1 |
| Market Trends | 33 | 1 |
| Big Pharmaceutical Companies Venturing into MAbs Market | 33 | 1 |
| Technology Trends | 33 | 1 |
| State-of-the-art R&D Technologies Expanding the Applications of MAbs to New Therapeutic Indications | 33 | 1 |
| New Screening Technologies to Foster Monoclonal Antibody Development | 33 | 1 |
| Product Trends | 33 | 1 |
| Research and Development Focus Shifted Towards Humanized and Fully Human MAbs | 33 | 1 |
| Horizontal Indication Expansion of Existing MAbs | 33 | 1 |
| Global MAbs Market Drivers | 34 | 1 |
| Gradual Growth in the Uptake of MAbs Have Driven the Monoclonal Antibody Sales Growth | 34 | 1 |
| Improved Side-effect Profiles and Tolerance of MAbs Therapy | 34 | 1 |
| Lack of Effective Conventional Therapies Accelerates Utilization of MAbs | 34 | 1 |
| Expanded Indications Opens up New Potential Patient Groups | 34 | 1 |
| Lack of Generics Augmented the Sales Growth of MAbs | 35 | 1 |
| Global MAbs Market Restraints | 35 | 1 |
| High Cost of MAbs Hampering the Growth of Treatment Population | 35 | 1 |
| Adverse Effects Generation of Antibodies against MAbs in Patients Receiving Monoclonal Antibody Therapy | 35 | 1 |
| Industry Challenges Majority of MAbs Receive Approvals as Last Option Therapies | 35 | 1 |
| Unmet Needs | 36 | 1 |
| Reduction in High Cost of MAb Therapies is the Major Unmet Need and it is also Responsible for Low Utilization by Patients | 36 | 1 |
| MAbs Do Not Cure Diseases; They either Treat Signs and Symptoms or Decelerate Cell Proliferation | 36 | 1 |
| Monoclonal Antibodies Market to 2017 - Breast Cancer (Adjuvant and Metastatic) | 37 | 27 |
| Overview | 37 | 1 |
| Introduction | 37 | 1 |
| Epidemiology | 38 | 1 |
| Diagnosis | 38 | 1 |
| Treatment | 39 | 1 |
| Prescription Population | 40 | 1 |
| Global | 40 | 2 |
| The US | 42 | 1 |
| Europe | 43 | 1 |
| ROW | 44 | 1 |
| Annual Cost of Therapy | 45 | 1 |
| Global | 45 | 1 |
| The US | 46 | 1 |
| Europe | 47 | 1 |
| ROW | 48 | 1 |
| Market Size | 49 | 1 |
| The US | 50 | 2 |
| Europe | 52 | 1 |
| ROW | 53 | 1 |
| Marketed Products | 54 | 1 |
| Herceptin (trastuzumab) | 54 | 1 |
| Product Overview | 54 | 1 |
| Mechanism of Action | 54 | 1 |
| Indications and Usage | 54 | 1 |
| Dosage | 54 | 1 |
| Pipeline Analysis | 55 | 1 |
| Phase lll | 56 | 2 |
| Phase ll | 58 | 3 |
| Phase l | 61 | 1 |
| Preclinical/Discovery | 62 | 1 |
| Promising Molecules | 63 | 1 |
| Pertuzumab (2C4, trade name Omnitarg) | 63 | 1 |
| Product Description | 63 | 1 |
| Mechanism of Action | 63 | 1 |
| Clinical Trials | 63 | 1 |
| Ramucirumab (IMC-1121B) | 63 | 1 |
| Product Description | 63 | 1 |
| Mechanism of Action | 63 | 1 |
| Clinical Trials | 63 | 1 |
| MAbs Market Size in Bone Metastases and Bone Loss Due to Cancer Therapy | 64 | 16 |
| Introduction | 64 | 1 |
| Epidemiology | 65 | 1 |
| Diagnosis | 65 | 1 |
| Treatment | 65 | 1 |
| Prescription Population | 66 | 1 |
| Global | 66 | 1 |
| The US | 67 | 1 |
| Europe | 68 | 1 |
| ROW | 69 | 1 |
| Annual Cost of Therapy | 70 | 1 |
| Global | 70 | 1 |
| The US | 71 | 1 |
| Europe | 72 | 1 |
| ROW | 73 | 1 |
| Market Size | 74 | 1 |
| Global | 74 | 1 |
| The US | 75 | 1 |
| Europe | 76 | 1 |
| ROW | 77 | 1 |
| Marketed Products | 78 | 1 |
| Xgeva (denosumab) | 78 | 1 |
| Product Overview | 78 | 1 |
| Mechanism of Action | 78 | 1 |
| Dosage | 78 | 1 |
| Pipeline Analysis | 79 | 1 |
| NDA Filed | 79 | 1 |
| Phase ll | 79 | 1 |
| Phase l | 79 | 1 |
| Preclinical/Discovery | 79 | 1 |
| MAbs Market Size in Relapsing-Remitting Multiple Sclerosis (RRMS) | 80 | 18 |
| Introduction | 80 | 1 |
| Epidemiology | 80 | 1 |
| Diagnosis | 80 | 1 |
| Treatment | 81 | 1 |
| Prescription Population | 81 | 1 |
| Global | 81 | 2 |
| The US | 83 | 1 |
| Europe | 84 | 1 |
| ROW | 85 | 1 |
| Annual Cost of Therapy | 86 | 1 |
| Global | 86 | 1 |
| The US | 87 | 1 |
| Europe | 88 | 1 |
| ROW | 89 | 1 |
| Market Size | 90 | 1 |
| Global | 90 | 1 |
| The US | 91 | 1 |
| Europe | 92 | 1 |
| ROW | 93 | 1 |
| Marketed Products | 94 | 1 |
| Description | 94 | 1 |
| Mechanism of Action | 94 | 1 |
| Indications and Usage | 94 | 1 |
| Dosage | 94 | 1 |
| Pipeline Analysis | 95 | 1 |
| Phase lll | 95 | 1 |
| Phase ll | 95 | 1 |
| Phase l | 96 | 1 |
| Preclinical/Discovery | 96 | 1 |
| Promising Molecules | 96 | 1 |
| Campath (Alemtuzumab) | 96 | 1 |
| Product Description | 96 | 1 |
| Mechanism of Action | 96 | 1 |
| Clinical Trials | 97 | 1 |
| Ocrelizumab | 97 | 1 |
| Product Description | 97 | 1 |
| Mechanism of Action | 97 | 1 |
| Clinical Trials | 97 | 1 |
| MAbs Market Size in Metastatic Non-Small Cell Lung Cancer (NSCLC) | 98 | 24 |
| Introduction | 98 | 1 |
| Epidemiology | 98 | 1 |
| Diagnosis | 98 | 2 |
| Prescription Population | 100 | 1 |
| Global | 100 | 1 |
| The US | 101 | 1 |
| Europe | 102 | 1 |
| ROW | 103 | 1 |
| Annual Cost of Therapy | 104 | 1 |
| Global | 104 | 1 |
| The US | 105 | 1 |
| Europe | 106 | 1 |
| ROW | 107 | 1 |
| Market Size | 108 | 1 |
| Global | 108 | 1 |
| The US | 109 | 1 |
| Europe | 110 | 1 |
| ROW | 111 | 1 |
| Marketed Products | 112 | 1 |
| Avastin | 112 | 1 |
| Description | 112 | 1 |
| Mechanism of Action | 112 | 1 |
| Indications and Usage | 112 | 1 |
| Dosage | 112 | 1 |
| Pipeline Analysis | 112 | 1 |
| Phase III | 113 | 1 |
| Phase II | 114 | 5 |
| Phase I | 119 | 1 |
| Promising Molecule | 120 | 1 |
| Necitimumab | 120 | 1 |
| Product Description | 120 | 1 |
| Mechanism of Action | 120 | 1 |
| Clinical Trials | 120 | 1 |
| Ramucirumab | 121 | 1 |
| Product Description | 121 | 1 |
| Mechanism of Action | 121 | 1 |
| Clinical Trials | 121 | 1 |
| Monoclonal Antibodies Market to 2017 - Rheumatoid Arthritis | 122 | 21 |
| Introduction | 122 | 1 |
| Epidemiology | 122 | 1 |
| Diagnosis | 122 | 1 |
| Treatment | 123 | 1 |
| Prescription Population | 124 | 1 |
| Global | 124 | 1 |
| The US | 125 | 1 |
| Europe | 126 | 1 |
| ROW | 127 | 1 |
| Annual Cost of Therapy | 128 | 1 |
| Global | 128 | 1 |
| The US | 129 | 1 |
| Europe | 130 | 1 |
| ROW | 131 | 1 |
| Market Size | 132 | 1 |
| Global | 132 | 1 |
| The US | 133 | 1 |
| Europe | 134 | 1 |
| ROW | 135 | 1 |
| Marketed Products | 136 | 1 |
| Rituxan | 136 | 1 |
| Description | 136 | 1 |
| Mechanism of Action | 136 | 1 |
| Remicade | 136 | 1 |
| Description | 136 | 1 |
| Dosage | 136 | 1 |
| Humira | 136 | 1 |
| Description | 136 | 1 |
| Mechanism of Action | 136 | 1 |
| Cimzia | 136 | 1 |
| Description | 136 | 1 |
| Mechanism of Action | 136 | 1 |
| Dosage | 137 | 1 |
| Simponi | 137 | 1 |
| Description | 137 | 1 |
| Mechanism of Action | 137 | 1 |
| Actemra | 137 | 1 |
| Product Description | 137 | 1 |
| Mechanism of Action | 137 | 1 |
| Dosage and Administration | 137 | 1 |
| Pipeline Analysis | 138 | 1 |
| Phase III | 138 | 1 |
| Phase II | 139 | 1 |
| Phase I | 140 | 1 |
| Preclinical/ Discovery Phase | 140 | 1 |
| Promising Molecule | 141 | 1 |
| Ofatumumab (Arzerra) | 141 | 1 |
| Product Description | 141 | 1 |
| Mechanism of Action | 141 | 1 |
| Clinical Trials | 141 | 1 |
| SAR153191(REGN88) | 141 | 1 |